To the Editor: Many beta cell growth factors have been identified, one of the most promising being glucagon-like peptide-1 (GLP-1), a peptide secreted from intestinal endocrine L-cells in response to nutrient ingestion. GLP-1 is rapidly cleaved and inactivated in vivo by dipeptidyl peptidase-4 (DPP-4), a ubiquitous serine protease. DPP-4 inhibitors (DPP-4i) have been shown to raise circulating levels of active GLP-1 and thus increase and maintain effective concentrations of this peptide reaching target tissues [1] . Studies in humans with type 2 diabetes have shown that DPP-4i therapy improves glucose tolerance [2] . In addition, DPP-4i treatments can preserve pancreatic beta cell mass in animal models of type 2 diabetes [3] and stimulate beta cell regeneration in streptozotocin-induced diabetic rats [4] .
Regarding deficits in pancreatic beta cell mass resulting from autoimmune (type 1) diabetes, the GLP-1 analogue, exendin-4, reversed diabetes in NOD mice; however, this required additional immunosuppressive therapy [5] . Addition of the gastrointestinal peptide hormone, gastrin, to GLP-1 therapy increased pancreatic beta cell mass and restored normoglycaemia in diabetic NOD mice without the use of immunosuppressants [6] . The objective of this study was to determine whether combination therapy with a DPP4i to raise endogenous levels of GLP-1, together with a proton pump inhibitor (PPI) to raise endogenous levels of gastrin, could reverse diabetes in NOD mice. Here, we report that such a combination therapy increased circulating levels of GLP-1 and gastrin in acutely diabetic NOD mice, and that pancreatic insulin content, insulin secretion and normoglycaemia were restored.
NOD female mice, age 6-8 weeks, were purchased from Taconic (Germantown, NY, USA). NOD-severe combined immunodeficient (NOD-scid) female mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA). The mice were housed and fed under specific pathogen-free conditions and cared for according to the guidelines of the Canadian Council on Animal Care. Diabetes onset was diagnosed by non-fasting blood glucose ≥10 mmol/l. Acutely diabetic NOD mice (blood glucose 10-16 mmol/l) were allocated to four groups within 4-7 days after diabetes onset and treated for 12 weeks with (1) the DPP-4i vehicle, 5 mg/ml methylcellulose in H 2 O given by oral gavage once daily and the PPI vehicle, PBS given by s. c. injection twice daily; (2) 10 mg/kg of a selective DPP-4i, 1-{[(3-hydroxy-1-adamantyl)amino]acetyl}-2-cyano-(S)-pyrrolidine (Dalton Chemical Laboratories, Toronto, ON, Canada) given by oral gavage once daily; (3) 30 mg/kg of a PPI, pantoprazole (Nycomed, Oakville, ON, Canada) given by s. c. injection twice daily; and (4) 10 mg/kg DPP-4i and 30 mg/kg PPI.
Acutely diabetic NOD mice treated with vehicle became progressively more hyperglycaemic (≥25 mmol/l) and were killed within 6 weeks (Fig. 1a) . Treatment with DPP-4i restored normoglycaemia in three of eight mice (38%) (Fig. 1b) and PPI was effective in three of nine mice (33%) (Fig. 1c) . In contrast, the combination of DPP-4i and PPI restored normoglycaemia in six of eight mice (75%) (Fig. 1d) . The plasma active GLP-1 level was increased threefold by DPP-4i demonstrating protection of GLP-1 from degradation by DPP-4 enzyme; this increase in GLP-1 was not changed by additional treatment with PPI (Fig. 1e) . The serum gastrin level was significantly increased by PPI demonstrating the expected elevation of gastrin production; however, addition of DPP-4i treatment did not change the serum gastrin level achieved by PPI treatment (Fig. 1f) . Treatments with DPP-4i and PPI given as single agents did not significantly increase plasma C-peptide or pancreatic insulin content compared with vehicle treatment, whereas combined DPP-4i and PPI treatments significantly increased plasma C-peptide (Fig. 1g) and pancreatic insulin content (Fig. 1h) . In a follow-up study with more acutely diabetic NOD mice (blood glucose 10-16 mmol/l), we found that normoglycaemia (3.5-7.0 mmol/l) was restored in 17 of 21 mice (81%) after 9 weeks of treatment with the combination of DPP-4i and PPI, compared with four of 14 mice (27%) treated with DPP-4i alone (p<0.01), four of 14 mice (27%) treated with PPI alone (p<0.01) and zero of 15 mice treated with vehicle (p<0.01); analysis was by one-way ANOVA and Dunnett's multiple comparison tests.
DPP-4 inhibition and consequent elevation of plasma GLP-1 levels was recently reported to partially decrease diabetes incidence in NOD mice [7] . Here, we found that DPP-4 inhibition after diabetes onset in NOD mice raised plasma GLP-1 levels threefold and restored normoglycae- Fig. 1 Acutely diabetic NOD mice were treated with vehicle (a), 10 mg/kg DPP-4i once daily (b), 30 mg/kg PPI twice daily (c) and both 10 mg/kg DPP-4i and 30 mg/kg PPI (d) for 12 weeks. Blood glucose concentrations were measured weekly and are shown for individual mice for 12 weeks or until blood glucose was ≥25 mmol/l and the mice were killed. Normoglycaemia (blood glucose 3.5-7.0 mmol/l, shaded bar) was determined in NOD-scid mice. e Mouse active GLP-1-(7-36)amide in plasma was measured by an ELISA electrochemiluminescence assay (Meso Scale Discovery, Gaithersburg, MD, USA). Serum gastrin (f) was measured using a RIA kit for the major circulating forms of human or mouse gastrin (MP Biomedicals, Orangeburg, NY, USA). C-peptide in plasma (g) was measured using a RIA kit specific for mouse C-peptide (Linco Research, St Charles, MO, USA). Pancreatic insulin content (h) was measured in ethanolic extracts of pancreas using a RIA kit for mouse insulin (Linco). e-f Mean±SE values are shown for all eight to nine mice in each group at the end (≤12 weeks) of the treatments indicated. *p<0.05, **p<0.01 vs vehicletreated mice (DPP-4i 0 mg/kg, PPI 0 mg/kg), analysed by one-way ANOVA and Dunnett's multiple comparison test mia in some of the mice; however, elevation of the serum gastrin level by concomitant PPI therapy potentiated the effects of DPP-4i treatment and normoglycaemia was restored in most of the mice; also plasma C-peptide and pancreatic insulin content were significantly increased by the combination therapy. DPP-4 inhibition increases endogenous levels of gastric inhibitory polypeptide (GIP) and GLP-1, both of which can mediate the glucoregulatory actions of DPP-4 inhibition [8] . It is possible, therefore, that GIP, as well as GLP-1, might have contributed to the reversal of diabetes by DPP4i in this study. A recent report, however, suggests that GLP-1 and not GIP has the major role in mediating DPP-4i effects on beta cell survival and function in mice [9] . The beneficial effect of PPI therapy on beta cell function and glucoregulation observed here is likely to be due to elevation of serum gastrin induced by PPI, because PPIinduced endogenous hypergastrinaemia has been reported to regenerate the endocrine pancreas and improve glucose tolerance after partial pancreatectomy in rats [10] , as well as after pancreatoduodenectomy in humans [11] . The results of this study suggest that DPP-4i and PPI combination therapy may offer a promising strategy for correction of the beta cell deficit and insulin deficiency in type 1 diabetes.
